Sanofi Pasteur's Investigational Dengue Vaccine Hits Main Goal Showing Efficacy In Phase 3 Trial

(Reuters) - Sanofi said on Monday that a late-stage clinical study showed that its dengue vaccine candidate met its main goal and was highly effective against severe cases of the disease.

The French drugmaker's Sanofi Pasteur division intends to file for registration for the vaccine in several endemic countries next year, it said in a statement.

"Subject to regulatory approval, the world's first dengue vaccine could be available in the second half of 2015," Sanofi said.

Help employers find you! Check out all the jobs and post your resume.

Back to news